Recovery of sales in the health food business and expansion of product formats and proposal capabilities
First written in FY2021. 7 of 17 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
0 other companies' latest entry also says "Dropped".
- FY2026DroppedAnnual report
「The company has completed its withdrawal from this business as scheduled at the end of the current fiscal year.」
The previous focus on recovering health food business sales and expanding product formats effectively ended as a continuing growth measure upon completion of the business withdrawal. - FY2026-H1ReframedAnnual report
「Although we had expected sales to decline as a result of the business withdrawal announced on 13 June 2025, sales increased year on year because orders remained firm.」
The company states that, in addition to its previous sales recovery measures for the health food business, it announced its withdrawal from the business on 13 June 2025 and shifted its business policy. - FY2025-H1AdvancedAnnual report
「Sales increased year on year for the second consecutive quarter, mainly because sales of the new large-scale OEM project launched in the third quarter of the previous fiscal year grew. The improving trend in the cost ratio also continued, supported by higher factory utilization during the previous fiscal year and a review of selling prices.」
The recovery measures for the health food business continued to benefit from growth in sales of the new large-scale OEM project and improvement in the cost ratio through higher factory utilization and a review of selling prices. - FY2024-Q3AdvancedAnnual report
「Sales for the business as a whole increased, supported by the recovery in order volumes for some core OEM products that had declined year on year and the launch of a new large-scale OEM project in February.」
The recovery in orders for some core OEM products and the launch of a new large-scale OEM project in February advanced the recovery of health food business sales. Improvement in the cost ratio through higher factory utilization and the pass-through of higher prices was also indicated. - FY2024-Q2AdvancedAnnual report
「Although order volumes declined for some core OEM products, the business as a whole maintained sales at approximately the year-earlier level through the acquisition of new projects. The manufacturing cost ratio also showed an overall improving trend as a result of higher factory utilization from the second quarter, and we expect this trend to continue.」
The acquisition of new projects kept health food business sales approximately at the year-earlier level, while higher factory utilization from the second quarter put the manufacturing cost ratio on an improving trend. - FY2024-Q1SoftenedAnnual report
「Sales declined from the year-earlier period, mainly because orders for some core OEM products failed to grow. Our in-house products for television mail-order sales performed well in large-scale promotions and remained firm.」
Although in-house products for television mail-order sales remained firm, recovery in total health food business sales did not progress because of sluggish orders for some core OEM products. Sales declined 10.8% year on year. - FY2023WorsenedAnnual report
「We expect the health food market to continue growing moderately for the time being, but sales of existing products were weak in the current fiscal year, resulting in sales and earnings falling short of plan. We will work to restore sales promptly and improve earnings by steadily acquiring new projects and reviewing our production structure.」
Sales and earnings fell short of plan because of weak performance by existing products. Although recovery measures are continuing, the business deteriorated into an operating loss for the full fiscal year. - FY2023-Q3SoftenedAnnual report
「We had initially expected orders for the OEM product launched in the previous year to remain sluggish, but sales declined significantly from the year-earlier period as declines in orders for existing products coincided with delays in launching new projects.」
Delays in launching new projects and declines in orders for existing products limited progress in the health food business's sales recovery measures, worsening both sales and earnings. - FY2023-Q2SoftenedAnnual report
「Sales of the relatively large OEM product launched in the same period of the previous year were sluggish, and orders declined as anticipated. Several existing products also experienced declining orders. Although the company converted several new beauty and health-related projects into sales and sales of its own products remained strong, these were insufficient to offset the decline.」
The company reported the conversion of new projects into sales and strong performance by its in-house products, but these gains could not offset declines in orders for existing OEM and existing products, limiting the effectiveness of its sales recovery measures. - FY2023-Q1SoftenedAnnual report
「Sales declined from the year-earlier period because a relatively large OEM new product had begun selling in the year-earlier period. Our in-house products for television mail-order sales performed well in large-scale promotions and remained strong.」
Although in-house products for television mail-order sales performed well, total health food business sales declined and the business posted an operating loss due to the unfavorable comparison following the launch of a large-scale OEM new product in the year-earlier period. - FY2022AdvancedAnnual report
「We expect the health food market to continue growing moderately for the time being, and we will seek to expand sales through the continued acquisition of projects. We will strengthen product development for areas expected to grow, such as foods with function claims and products for older consumers, using our accumulated recipe portfolio.」
In addition to the recovery provided by existing customers and new OEM jelly projects, the company identifies strengthened development of foods with function claims and products for older consumers as a new avenue for growth. - FY2022-Q3AdvancedAnnual report
「Sales of OEM jelly products increased as sales to existing customers remained generally firm and the acquisition of new customers and projects progressed smoothly.」
For the recovery measures in the health food business, sales to existing customers remained firm and the acquisition of new customers and projects progressed smoothly, bringing cumulative nine-month sales to ¥667.817 million. - FY2022-Q2AdvancedAnnual report
「Sales of OEM jelly products to customers that operate mail-order businesses continued to perform well. The company is also making progress in acquiring new projects for T-pouch and shot-type products, with sales gradually increasing.」
The recovery measures for the health food business are showing progress through strong sales to mail-order customers, the acquisition of new projects, and increased sales of T-pouch and shot-type products. - FY2022-Q1AdvancedAnnual report
「For OEM jelly products, sales to customers that operate mail-order businesses continued to perform well, as in the previous fiscal year, and we also secured a new large-scale project. New projects for T-pouch and shot-type products are also gradually increasing.」
The recovery measures for the health food business are showing progress through strong sales to existing customers, the acquisition of new large-scale projects, and an increase in new projects for T-pouch and shot-type products. - FY2021First statedAnnual report
「In the health food business, we consider the recovery of sales, which declined following the completion of a large OEM project and the downsizing of unprofitable operations, to be an urgent priority. In addition to our existing stick-type products, we are actively pursuing sales of T-pouch and shot-type products, which have larger capacities.」
To recover sales lost following the completion of large OEM projects and other factors, the company is adding T-pouch and shot-type products and pursuing an active sales campaign.